Scientific Committee

Click on the image to view biography

Debananda Pati

Professor, Baylor College of Medicine, USA

Professor Pati is a highly accomplished cancer biologist who is an internationally recognized leader in the field of chromosomal cohesion and Separation and its role in carcinogenesis. He has a highly impressive track record not only in basic biology of chromosomal cohesion and separation, but devising novel and innovative approaches to target the cohesin pathway for treating refractory human cancers.  He is widely recognized nationally and internationally as a creative and innovative scientist and is specifically recognized for his identification and targeting of the cohesin-protease, Separase for cancer therapy. Separase, an enzyme important for resolving chromosomal cohesion, is a novel oncogene and promoter of aneuploidy and tumorigenesis that Professor Pati demonstrated is an ideal target for cancer therapy. His laboratory was first to show that Separase is an oncogene and aneuploidy promoter.  In a series of publications in high impact journals, Professor Pati and his colleagues demonstrated that overexpression of Separase in mouse models not only induces aneuploidy but also results in tumorigenesis.

Shi-Ming Tu

Shi-Ming Tu

Clinical Professor , University of Texas, M.D. Anderson Cancer Center, USA

Shi-Ming Tu, M.D., received his bachelor degree from the Johns Hopkins University, Baltimore, Maryland, and medical degree from Washington University, St. Louis, Missouri. He completed his medical oncology fellowship at the University of Texas, M.D. Anderson Cancer Center,Houston, Texas, where he is currently a clinical professor in the Department of Genitourinary Medical Oncology.Dr. Tu is a clinician, researcher, educator, and author. He specializes in the treatment of prostate and testicular cancers. His research interests include bone metastasis, intratumoral heterogeneity, and cancer stem cells. He has published more than 100 peer-reviewed articles. His previous book, Origin of Cancers: Clinical Perspectives and Implications of a Stem-Cell Theory of Cancer, was published by Springer in 2010. His new book, Story of Hydra: Portrait of cancer as a stem-cell disease, will be published in fall of 2018.

Davide Abed El Rahman

Davide Abed El Rahman

Doctor, G. Salvini Hospital , ITALY

Degree in Medicine and Surgery with honors, “laude” and winning of “ Nicolosi award " at Faculty of Medicine University of Palermo  after discussing the urological thesis entitled l:α-lytic Medical treatment of benign prostatic hyperplasia: the problem of Floppy Iris Syndrome. Review of the literature and results of an experimental protocol for the evaluation of preoperative risk with the measurement of pupil size

Ashok Srivastava

Chief Executive Officer & Chief Medical Officer, ClinFomatrix, and Cure Pharmaceuticals Inc, USA

Dr. Ashok Srivastava is  Chief Executive Officer  and Chief Medical Officer  of ClinFomatrix Oncology and  Chief Executive Officer  of Cure Pharmaceuticals, Inc., USA.. He was also founder and Chief Medical Officer of CareBeyond - A Radiation Cancer Center in USA. He has more than 17 years of experience in drug development , medical affairs and commercialization of cancer drugs including radiopharmaceutical  and  supportive care; Phase I – 4, and marketing commercialization of  immuno-oncology, hematology, oncology and radio pharmacetuical drugs in USA , EU and Japan.  He is leader in Cancer Drug Development  Worldwide  large Phase 2 and 3 clinical  trials in many countries.  He  contributed to 21-INDs and 7-NDAs of Cancer Drugs and supportive care, acquisition /merger of  pharma and drug  for more than $300 million .  He received his clinical, medical training  & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center,  Daiichi, Sumitomo, Pharmacia, Pfizer,  Sopherion Oncology., Eisai Oncology, and Spectrum Pharmaceuticals. He received his  Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India ; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Nagasaki, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and  latuda (Lurasidone) for schizophrenia . He is one of the inventors of Japanese encephalitis vaccine (IXIARO) . He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of  Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor  to Poniard Pharmaceutical for small cell lung cancer in USA, EU and India.  He is member of numerous prestigious organizations; America’s Top Oncologist of the years 2007- 2011, Breast Cancer Foundation , Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer.  Dr. Srivastava is a strategic  medical advisor and Board Member to several pharma in USA for clinical, regulatory  and supervises cancer drug development . Recently Dr. Srivastava was awarded membership of Japan External Trade  Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of  hematology, Oncology  drugs and built a global drug safety and pharmacovigilance companies in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance  congress in London, UK , China and India in Jan 2012, 2013 and 2017.  Dr. Srivastava brought 2 cancer drugs & a vaccine in global market  for  approx  3 – 3.5 billion $ global sales.  He serves as board of director s for oncology virtual pharma companies in USA .

Aurelija Vaitkuviene

Aurelija Vaitkuviene

Afilliated senior researcher, Vilnius University, LITHUANIA.

Aurelija Vaitkuviene received her medical degree and completed obstetrics-gynecology fellowship at Vilnius University and clinics. She defended Doctoral thesis on Sonoscopy in Placenta previa. She obtained Laser medicine training from Wensky Laser Centre (USA), Lund University Laser Centre (Sweden), hysteroscopy-at Karolinska University (Sweden), colposcopy-at Lund University (Sweden), Greifswald University (Germany). She worked as obstetrician-gynecologist, associated professor, senior researcher. She headed Laser surgery/Biomedical optics department at Institute of Applied Research at Vilnius University. Currently Affiliated Senior Researcher, Biomedical diagnostics group leader at Institute of Photonics and Nanotechnology of Physics faculty, Vilnius University. She specializes in optical medical devices creation, clinical investigation, inter disciplinary teaching. She is founding member and scientific committee member at International Academy for Laser Surgery and Medicine (Florence), Past President (2013-2015) of International Society for Laser Surgery and Medicine, International Phototherapy Association, Past Chair of Colposcopy section of Lithuanian Association of Obstetricians and gynecologists. She was a President of EUROGIN –EAST conference, World Laserology Congress, Vilnius 2013, scientific committee member of Correlation optics International congress. Delivered presentations at International Society of Ultrasound in Obsterics and Gynecology (ISUOG), International Federation of Obstetrics and Gynecolgy (FIFA), International organization for optics and photonics (SPIE), American Association for Cancer Research (AACR), Frontiers in Cancer research, Cancer Science and Therapy, EUROGYN, European Cervical Cancer Association (ECCA), Minimal Invasive Gynecology Association (AAGL)) meetings. She published peer reviewed articles and 2 books in Lithuanian language “Laser surgery basics”,” Minimal invasive gynecology”,1-2 vol. She was at Editorial board of “HPV Today” (coordinator for Russia and NIS)”, currently reviewer for “Lasers in Medical Science”. She is Past President of Women NGO “Soroptimist International” Lithuanian Union.

Cancer 2018 Scientific committee

Graeme Williams

Physician, Scientist, Harvard

Physician, Scientist, Molecular Endocrinologist, (Molecular and CellularMedicine Group, University of Reading, UK) and Harvard Clinical ResearchScholar, (Royal College of Physicians (Lond)/UCL)Current Research: The role of aromatase, GPER, cortisol, poor carbohydratedietary choices and chemical exposures, upon the pathogenesis of obesity,NAFLD, insulin resistance, type two diabetes, breast and prostate cancer, andsexual dysfunction in men and women.In other words:- how stress, injudicious diets and everyday chemicalexposures, cause obesity, metabolic syndrome, type 2 diabetes and hormonerelatedcancer.

About Conference

Linkin Science invites all the participants from all over the world to attend 2nd Global Cancer Meet & Expo during August 27-29, 2018 at Rome, Italy which includes Keynote presentations, Oral talks, Poster presentations and Exhibitions.
The pace of cancer research breakthroughs has continued in the past year and the Conference aims to showcase these scientific developments that are already resulting in measurable benefits for patients. some of the highlights of the multi-disciplinary program include world-leading experts speaking on early detection and prevention of cancer, cancer Biomarkers, Prostate Cancer, Breast cancer, Lung Cancer, new developments in cancer treatment, cancer related symptoms in advanced disease and communicating cancer research to the public.
 Global Cancer Meet will also provide the excellent opportunity to meet experts, exchange information, and strengthen the collaboration among Directors, Researchers, Associate Professors, and Scholars from both academia and industry.
2nd Global Cancer Meet and Expo  is anticipating participants from 20 and more countries across the globe and the three day conference will provoke Plenary sessions, Keynote speeches, Oral and Poster presentations. This program provides three days in depth discussions on recent advancements and insights in Cancer research.
Our pleasure to meet you in upcoming event…!!!
  • To facilitate opportunities for networking, collaboration and exchange of ideas with internationally renowned leaders Cancer research.
  • To identify research and practice based innovations in optimizing Cancer research and development.
  • To debate gaps and priorities for sustainable development Cancer research and development.
  • Why to attend?
  • The entire world is focused on learning about cancer science  and Therapy , so this is the best opportunity to reach largest meeting of participants from the Cancer community. Distribute information, conduct presentations and meet with current and potential scientists.  Make a splash with new researches and its developments in this 2-day event at Cancer Science 2018 conference. World-renowned speakers, recent techniques, developments and newest updates in cancer treatment  are major parts of this conference.
  • Establishing their academic and professional relationships.
  • Improving their morale and confidence of presenting research in an international platform.
  • Interacting with expertise in their respective departments.
  • Clearing your inhibitions of adjusting to the foreign environment.
  • Providing a holistic experience of academic tourism.
Target Audience:
  • Academicians
  • Medical Colleges
  • Research faculty
  • Students
  • Oncologists
  • Pathologists
  • Cancer & Oncology Societies Professionals
  • Diagnostic laboratory professionals          
  • Presidents & Vice Presidents
  • Directors/Managers/CEO’s
  • Bio-Medical Company professionals
  • Industry Professionals
  • Corporate Cancer Research Professional
  • Pharmacists Business Entrepreneurs
  • Medical Devices Companies
  • Biotechnology Companies
  • Marketing, Advertising and Promotion Agency Executives .

Scientific Sessions

Cancer Biomarkers

cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Cancer biomarkers, particular those associated with genetic mutations or epigenetic alterations, often offer a quantitative way to determine when individuals are predisposed to particular types of cancers. Cancer biomarkers can also be useful in establishing a specific diagnosis. This is particularly the case when there is a need to determine whether tumors are of primary or metastatic origin. Another use of biomarkers in cancer medicine is for disease prognosis, which take place after an individual has been diagnosed with cancer. Cancer biomarkerscan also offer value in predicting or monitoring cancer recurrence. 

Cancer therapeutics

Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality. Complete removal of the cancer without damage to the rest of the body (that is, achieving cure with near-zero adverse effects) is the ideal goal of treatment and is often the goal in practice. Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of one or both of the genes. The incidence of concurrent cancer during pregnancy has risen due to the increasing age of pregnant mothers and due to the incidental discovery of maternal tumors during prenatal ultrasound examinations. Cancer treatment needs to be selected to do least harm to both the woman and her embryo/fetus. In some cases a therapeutic abortion may be recommended. 

Cancer Diagnostics

Cancer Diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. Cancer Diagnostics plays an important role throughout your cancer treatment. Physical Examination, Laboratory tests, Biopsy, Imaging tests, Nuclear medicine scans, Endoscopy, Genetic tests are some of the diagnostic tests which are being carried out in the present world.

Cancer Immunology

Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells. Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction of host and tumor cells, three essential phases have been proposed: elimination, equilibrium and escape, which are designated the ‘three E’s'. The principles of cancer immunoediting have set the foundations for understanding the dual host-protective and tumor sculpting actions of immunity on cancer and establishing the basis for novel individualized cancer immunotherapies.

Clinical Research in Cancer

Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Traditional clinical trials are straightforward and purposely simple. Traditional clinical trials focus on large populations. Clinical trials keep getting bigger, making therapies more expensive and delaying their availability to patients.

Cancer stem cells and drug resistance

Cancer stem cells are cancer cells that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumor-forming), perhaps in contrast to other non-tumorigenic cancer cells. The "mutation in stem cell niche populations during development" hypothesis claims that these developing stem populations are mutated and then reproduce so that the mutation is shared by many descendants. These daughter cells are much closer to becoming tumors and their numbers increase the chance of a cancerous mutation. De-differentiation of mutated cells may create stem cell-like characteristics, suggesting that any cell might become a cancer stem cell. The design of new drugs for targeting CSCs requires understanding the cellular mechanisms that regulate cell proliferation. The first advances in this area were made with hematopoietic stem cells (HSCs) and their transformed counterparts in leukemia, the disease for which the origin of CSCs is best understood. 

Breast cancer

Breast cancer is cancer that develops from breast tissue.  Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, or a red scaly patch of skin. Risk factors for developing breast cancer include being female, obesity, lack of physical exercise, drinking alcohol, hormone replacement therapy during menopause, ionizing radiation, early age at first menstruation, having children late or not at all, older age, and family history. Women may reduce their risk of breast cancer by maintaining a healthy weight, drinking less alcohol, being physically active and breastfeeding their children. High levels of physical activity reduce the risk of breast cancer. The management of breast cancer depends on various factors, including the stage of the cancer and the age of the patient. Increasingly aggressive treatments are employed in accordance with the poorer the patient's prognosis and the higher the risk of recurrence of the cancer following treatment. Prognosis is usually given for the probability of progression-free survival (PFS) or disease-free survival (DFS). These predictions are based on experience with breast cancer patients with similar classification. Treatments are being evaluated in trials. This includes individual drugs, combinations of drugs, and surgical and radiation techniques Investigations include new types of targeted therapy, cancer  vaccines, oncolytic virotherapy, and immunotherapy.

Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other parts of the body, particularly the bones and lymph nodes. A complete understanding of the causes of prostate cancer remains elusive. The primary risk factors are obesity, age and family history. Prostate cancer is very uncommon in men younger than 45, but becomes more common with advancing age. The only test that can fully confirm the diagnosis of prostate cancer is a biopsy, the removal of small pieces of the prostate for microscopic examination. However, prior to a biopsy, less invasive testing can be conducted. Men who get regular exercise may have a slightly lower risk, especially vigorous activity and the risk of advanced prostate cancer. The first decision to be made in managing prostate cancer is whether treatment is needed. Prostate cancer, especially low-grade forms found in elderly men, often grows so slowly that no treatment is required. Treatment of aggressive prostate cancers may involve surgery (i.e. radical prostatectomy), radiation therapy including brachytherapy (prostate brachytherapy) and external beam radiation therapy, high-intensity focused ultrasound (HIFU), chemotherapy, oral chemotherapeutic drugs (Temozolomide/TMZ), cryosurgery, hormonal therapy, or some combination.  

Lung Cancer

Lung cancer is a tumor growth characterized by uncontrolled cell growth in tissues of the lung. The major symptoms include breathing difficulties, pain in the chest area, coughing with blood, Loss of appetite, recurring infections. The common causes include Smoking, exposure to radon gas, asbestos, ionizing radiation, air pollution. Lung cancer may also occur due to genetic factors. Diagnosis of lung cancer includes various methods like Chest X-ray, Computed Tomography (CT), Biopsy, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET). Lung cancers are classified in to adenocarcinoma, squamous carcinoma, small cell carcinoma and others. Primary lung cancers themselves most commonly metastasize to the brain, bones, liver and adrenal glands. The evaluation of non-small-cell lung carcinoma (NSCLC) staging uses the TNM classification. Smoking prevention and smoking cessation are effective ways of preventing the development of lung cancer. Treatment for lung cancer depends on the cancer's specific cell type, how far it has spread, and the person's performance status. Common treatments include palliative care, surgery, chemotherapy, and radiation therapy. Targeted therapy of lung cancer is growing in importance for advanced lung cancer.

Cancer prevention and Management

Reducing the risk of certain cancers may be possible through dietary and other lifestyle changes. Other lifestyle changes reduce the risk of several types of cancer. Early detection of cancerous or precancerous growths can save lives. People with cancer want to do everything they can to combat the disease, manage its symptoms, and cope with the side effects of treatment. Many turn to complementary health approaches.

Surgical Oncology and Radiology

Surgery is the oldest form of cancer treatment, and for most patients, part of the curative plan includes surgery. The most important part of the consultation with the surgeon is a complete history and physical exam. Surgery is used to diagnose stage and treat cancer, and certain cancer-related symptoms. Surgery plays an important role in the management of both early cancers as well as advanced cancers in combination with chemotherapy and radiotherapy

Scientific Sessions

Abstract Submission : July 31, 2018

Early Bird Registration : July 30, 2018

  • Cancer Biomarkers
  • Cancer therapeutics
  • Cancer Diagnostics
  • Cancer Immunology
  • Clinical Research in Cancer
  • Metastatic carcinoma
  • OncoGenomics
  • Cell Biology and Cancer
  • Cancer stem cells and drug resistance
  • Breast cancer
  • Prostate Cancer
  • Lung Cancer
  • Other major cancer types
  • Cancer Prognosis
  • Cancer prevention and Management
  • Surgical Oncology and Radiology
  • Sarcomas and Carcinomas

Registration Categories

Abstract Submission : July 31, 2018

Early Bird Registration : July 30, 2018


Various awards will be given to the participants for scientific presentations.

GCME (Global Cancer Meet and Expo) anticipates being able to provide funding to assist some participants attending from Lower and Middle Income group Countries to present their research at the conference.  Participants desiring to be considered for one of these awards need to specify their interest after their submission of the required abstract. Selected participants will receive a sum of $250 to $1,000 (USD) scholarship Under three categories

1.     Outstanding Submitted Abstract for the GCME conference

2.     Best Research of the conference as evaluated by the Scientific Committee

3.     Young Researcher Award under YRF category to encourage budding scientists/ researchers.

4.     Best Poster Presentation Award 

Decisions will be made based on evaluation of the submitted abstract by the scientific committee and amount of funds available.

We want you to grab this opportunity and participate in the conference.

Linkin Science and on behalf of the Scientific Committee Members of the Global Cancer Meet-2017 we congratulate the winners on grabbing the Global Excellence Awards. We wish you a great success for your future endeavours.

Past Conference Report

Global Cancer Meet & Expo 2017 Past Conference Repor:

Linkin Science has successfully completed Global Cancer Meet & Expo conference which was held during December 04-06, 2017 in Dubai. We thank all our expertise Scientific Committee Members who offered a constant support for the conference.

Linkin Science would like to greet all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation.

The keynote speakers include:

  • Xiaoping Sun, University of Texas MD Anderson Cancer Center, USA
  • Debananda Pati, Baylor College of Medicine, USA
  • Yun Gong, University of Texas MD Anderson Cancer Center, USA
  • Sheik Mohammad Fazle Akbar, Toshiba General Hospital, Japan
  • Ahmed Bouzidi ,CEO of Vaxeal Group, Switzerland


    The Global Excellence award winners for Cancer Meet 2017 are: 

    • Shafaq Maqsood, Shaukat Khanum Memorial Cancer hospital and Research, Pakistan (Poster category)
    • Ambreen Muzaffar, Shifa International Hospitals LTD, Pakistan (Poster Category)
    • Zarka Samoon, Aga Khan University Hospital, Pakistan (For Young Researcher Forum Category)

The 2nd Global Cancer Meet & Expo is scheduled during August 27-29, 2018 at ROME in ITALY. Hope to see you all at this international platform to explore your research in Oncology and Cancer research.

Conference Venue

Hotel Mercure Roma West,  ROME, Italy

Need Help ? Write to Us